Acquired Multi-Drug Resistant Tuberculosis--Buenaventura, Colombia, 1998

Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Acquired Multi-Drug Resistant Tuberculosis--Buenaventura, Colombia, 1998

Morbidity and Mortality Weekly Report (09/18/98) Vol. 47, No. 36

This article presents the findings of the first investigation of multi-drug resistant tuberculosis (MDR-TB) in Colombia. The study found high rates of drug resistance among TB patients who had a history of treatment for an average of 3.5 years. Sixty-seven percent of patients had resistance to two first-line therapies (isoniazid and rifampin). The high level of drug resistance among patients with a long history of active TB disease points to the need for improved treatment strategies, such as expanded use of directly observed therapy (DOT). With adequate treatment, over 80 percent of MDR-TB cases can be cured. The spread of multi-drug resistant TB is an increasing global threat. Both increased vigilance to treatment and international collaboration will be essential to eliminate this serious public health problem.

980918
AD981838

Copyright © 1998 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.